IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v14y2023i1d10.1038_s41467-022-35431-x.html
   My bibliography  Save this article

Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer

Author

Listed:
  • Song Li

    (Cheeloo College of Medicine, Shandong University)

  • Wenbin Yu

    (Cheeloo College of Medicine, Shandong University)

  • Fei Xie

    (Cheeloo College of Medicine, Shandong University)

  • Haitao Luo

    (Shenzhen Yucebio Technology Co., Ltd., Shenzhen)

  • Zhimin Liu

    (Zibo Municipal Central Hospital, Binzhou Medical College)

  • Weiwei Lv

    (Cheeloo College of Medicine, Shandong University)

  • Duanbo Shi

    (Cheeloo College of Medicine, Shandong University)

  • Dexin Yu

    (Cheeloo College of Medicine, Shandong University)

  • Peng Gao

    (Cheeloo College of Medicine, Shandong University)

  • Cheng Chen

    (Cheeloo College of Medicine, Shandong University)

  • Meng Wei

    (Cheeloo College of Medicine, Shandong University)

  • Wenhao Zhou

    (Shenzhen Yucebio Technology Co., Ltd., Shenzhen)

  • Jiaqian Wang

    (Shenzhen Yucebio Technology Co., Ltd., Shenzhen)

  • Zhikun Zhao

    (Shenzhen Yucebio Technology Co., Ltd., Shenzhen)

  • Xin Dai

    (Shandong Provincial Hospital of Traditional Chinese Medicine)

  • Qian Xu

    (Cheeloo College of Medicine, Shandong University)

  • Xue Zhang

    (Cheeloo College of Medicine, Shandong University)

  • Miao Huang

    (Cheeloo College of Medicine, Shandong University)

  • Kai Huang

    (Cheeloo College of Medicine, Shandong University)

  • Jian Wang

    (Cheeloo College of Medicine, Shandong University)

  • Jisheng Li

    (Cheeloo College of Medicine, Shandong University)

  • Lei Sheng

    (Cheeloo College of Medicine, Shandong University)

  • Lian Liu

    (Cheeloo College of Medicine, Shandong University)

Abstract

Despite neoadjuvant/conversion chemotherapy, the prognosis of cT4a/bN+ gastric cancer is poor. Immune checkpoint inhibitors (ICIs) and antiangiogenic agents have shown activity in late-stage gastric cancer, but their efficacy in the neoadjuvant/conversion setting is unclear. In this single-armed, phase II, exploratory trial (NCT03878472), we evaluate the efficacy of a combination of ICI (camrelizumab), antiangiogenesis (apatinib), and chemotherapy (S-1 ± oxaliplatin) for neoadjuvant/conversion treatment of cT4a/bN+ gastric cancer. The primary endpoints are pathological responses and their potential biomarkers. Secondary endpoints include safety, objective response, progression-free survival, and overall survival. Complete and major pathological response rates are 15.8% and 26.3%. Pathological responses correlate significantly with microsatellite instability status, PD-L1 expression, and tumor mutational burden. In addition, multi-omics examination reveals several putative biomarkers for pathological responses, including RREB1 and SSPO mutation, immune-related signatures, and a peripheral T cell expansion score. Multi-omics also demonstrates dynamic changes in dominant tumor subclones, immune microenvironments, and T cell receptor repertoires during neoadjuvant immunotherapy. The toxicity and post-surgery complications are limited. These data support further validation of ICI- and antiangiogenesis-based neoadjuvant/conversion therapy in large randomized trials and provide candidate biomarkers.

Suggested Citation

  • Song Li & Wenbin Yu & Fei Xie & Haitao Luo & Zhimin Liu & Weiwei Lv & Duanbo Shi & Dexin Yu & Peng Gao & Cheng Chen & Meng Wei & Wenhao Zhou & Jiaqian Wang & Zhikun Zhao & Xin Dai & Qian Xu & Xue Zhan, 2023. "Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    • Handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-022-35431-x
    DOI: 10.1038/s41467-022-35431-x
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-35431-x
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-35431-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Mikhail Shugay & Dmitriy V Bagaev & Maria A Turchaninova & Dmitriy A Bolotin & Olga V Britanova & Ekaterina V Putintseva & Mikhail V Pogorelyy & Vadim I Nazarov & Ivan V Zvyagin & Vitalina I Kirgizova, 2015. "VDJtools: Unifying Post-analysis of T Cell Receptor Repertoires," PLOS Computational Biology, Public Library of Science, vol. 11(11), pages 1-16, November.
    2. Mel Greaves & Carlo C. Maley, 2012. "Clonal evolution in cancer," Nature, Nature, vol. 481(7381), pages 306-313, January.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Jian-Xian Lin & Yi-Hui Tang & Hua-Long Zheng & Kai Ye & Jian-Chun Cai & Li-Sheng Cai & Wei Lin & Jian-Wei Xie & Jia-Bin Wang & Jun Lu & Qi-Yue Chen & Long-Long Cao & Chao-Hui Zheng & Ping Li & Chang-M, 2024. "Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial," Nature Communications, Nature, vol. 15(1), pages 1-12, December.
    2. Jia Wei & Xiaofeng Lu & Qin Liu & Yao Fu & Song Liu & Yang Zhao & Jiawei Zhou & Hui Chen & Meng Wang & Lin Li & Ju Yang & Fangcen Liu & Liming Zheng & Haitao Yin & Yang Yang & Chong Zhou & Ping Zeng &, 2023. "Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial," Nature Communications, Nature, vol. 14(1), pages 1-12, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Lichun Ma & Sophia Heinrich & Limin Wang & Friederike L. Keggenhoff & Subreen Khatib & Marshonna Forgues & Michael Kelly & Stephen M. Hewitt & Areeba Saif & Jonathan M. Hernandez & Donna Mabry & Roman, 2022. "Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer," Nature Communications, Nature, vol. 13(1), pages 1-17, December.
    2. Jani Huuhtanen & Dipabarna Bhattacharya & Tapio Lönnberg & Matti Kankainen & Cassandra Kerr & Jason Theodoropoulos & Hanna Rajala & Carmelo Gurnari & Tiina Kasanen & Till Braun & Antonella Teramo & Re, 2022. "Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    3. Saakian, David B. & Vardanyan, Edgar & Yakushkina, Tatiana, 2020. "Evolutionary model with recombination and randomly changing fitness landscape," Physica A: Statistical Mechanics and its Applications, Elsevier, vol. 541(C).
    4. Joseph G. Kern & Andrew M. Tilston-Lunel & Anthony Federico & Boting Ning & Amy Mueller & Grace B. Peppler & Eleni Stampouloglou & Nan Cheng & Randy L. Johnson & Marc E. Lenburg & Jennifer E. Beane & , 2022. "Inactivation of LATS1/2 drives luminal-basal plasticity to initiate basal-like mammary carcinomas," Nature Communications, Nature, vol. 13(1), pages 1-13, December.
    5. Christopher R S Banerji & Simone Severini & Carlos Caldas & Andrew E Teschendorff, 2015. "Intra-Tumour Signalling Entropy Determines Clinical Outcome in Breast and Lung Cancer," PLOS Computational Biology, Public Library of Science, vol. 11(3), pages 1-23, March.
    6. Yukinari Haraoka & Yuki Akieda & Yuri Nagai & Chihiro Mogi & Tohru Ishitani, 2022. "Zebrafish imaging reveals TP53 mutation switching oncogene-induced senescence from suppressor to driver in primary tumorigenesis," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    7. Kerry J. Laing & Werner J. D. Ouwendijk & Victoria L. Campbell & Christopher L. McClurkan & Shahin Mortazavi & Michael Elder Waters & Maxwell P. Krist & Richard Tu & Nhi Nguyen & Krithi Basu & Congron, 2022. "Selective retention of virus-specific tissue-resident T cells in healed skin after recovery from herpes zoster," Nature Communications, Nature, vol. 13(1), pages 1-13, December.
    8. Anna A Schönherz & Julie Støve Bødker & Alexander Schmitz & Rasmus Froberg Brøndum & Lasse Hjort Jakobsen & Anne Stidsholt Roug & Marianne T Severinsen & Tarec C El-Galaly & Paw Jensen & Hans Erik Joh, 2020. "Normal myeloid progenitor cell subset-associated gene signatures for acute myeloid leukaemia subtyping with prognostic impact," PLOS ONE, Public Library of Science, vol. 15(4), pages 1-21, April.
    9. Antonella Teramo & Andrea Binatti & Elena Ciabatti & Gianluca Schiavoni & Giulia Tarrini & Gregorio Barilà & Giulia Calabretto & Cristina Vicenzetto & Vanessa Rebecca Gasparini & Monica Facco & Iacopo, 2022. "Defining TCRγδ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    10. Shravana kumar chinnikatti, 2017. "Cancer and its Genomics in Transformation Era," Cancer Therapy & Oncology International Journal, Juniper Publishers Inc., vol. 7(2), pages 25-26, September.
    11. Duy Pham & Xiao Tan & Brad Balderson & Jun Xu & Laura F. Grice & Sohye Yoon & Emily F. Willis & Minh Tran & Pui Yeng Lam & Arti Raghubar & Priyakshi Kalita-de Croft & Sunil Lakhani & Jana Vukovic & Ma, 2023. "Robust mapping of spatiotemporal trajectories and cell–cell interactions in healthy and diseased tissues," Nature Communications, Nature, vol. 14(1), pages 1-25, December.
    12. Xiaodong Liu & Ke Zhang & Neslihan A. Kaya & Zhe Jia & Dafei Wu & Tingting Chen & Zhiyuan Liu & Sinan Zhu & Axel M. Hillmer & Torsten Wuestefeld & Jin Liu & Yun Shen Chan & Zheng Hu & Liang Ma & Li Ji, 2024. "Tumor phylogeography reveals block-shaped spatial heterogeneity and the mode of evolution in Hepatocellular Carcinoma," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    13. Michael D. Keller & Stefan A. Schattgen & Shanmuganathan Chandrakasan & E. Kaitlynn Allen & Mariah A. Jensen-Wachspress & Christopher A. Lazarski & Muna Qayed & Haili Lang & Patrick J. Hanley & Jay Ta, 2024. "Secondary bone marrow graft loss after third-party virus-specific T cell infusion: Case report of a rare complication," Nature Communications, Nature, vol. 15(1), pages 1-9, December.
    14. Caravagna Giulio, 2020. "Measuring evolutionary cancer dynamics from genome sequencing, one patient at a time," Statistical Applications in Genetics and Molecular Biology, De Gruyter, vol. 19(4-6), pages 1-12, December.
    15. Jolanda Sarno & Pablo Domizi & Yuxuan Liu & Milton Merchant & Christina Bligaard Pedersen & Dorra Jedoui & Astraea Jager & Garry P. Nolan & Giuseppe Gaipa & Sean C. Bendall & Felice-Alessio Bava & Kar, 2023. "Dasatinib overcomes glucocorticoid resistance in B-cell acute lymphoblastic leukemia," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    16. Juan Blanco-Heredia & Carla Anjos Souza & Juan L. Trincado & Maria Gonzalez-Cao & Samuel Gonçalves-Ribeiro & Sara Ruiz Gil & Dmytro Pravdyvets & Samandhy Cedeño & Maurizio Callari & Antonio Marra & An, 2024. "Converging and evolving immuno-genomic routes toward immune escape in breast cancer," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    17. Yuxuan Liu & Zhimin Gu & Hui Cao & Pranita Kaphle & Junhua Lyu & Yuannyu Zhang & Wenhuo Hu & Stephen S. Chung & Kathryn E. Dickerson & Jian Xu, 2021. "Convergence of oncogenic cooperation at single-cell and single-gene levels drives leukemic transformation," Nature Communications, Nature, vol. 12(1), pages 1-17, December.
    18. Zhongchao Li & Jing Liu & Bo Zhang & Jinbo Yue & Xuetao Shi & Kai Cui & Zhaogang Liu & Zhibin Chang & Zhicheng Sun & Mingming Li & Yue Yang & Zhao Ma & Lei Li & Chengsheng Zhang & Pengfei Sun & Jingta, 2024. "Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    19. Mike B. Barnkob & Yale S. Michaels & Violaine André & Philip S. Macklin & Uzi Gileadi & Salvatore Valvo & Margarida Rei & Corinna Kulicke & Ji-Li Chen & Vitul Jain & Victoria K. Woodcock & Huw Colin-Y, 2024. "Semaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    20. Thillai V. Sekar & Eslam A. Elghonaimy & Katy L. Swancutt & Sebastian Diegeler & Isaac Gonzalez & Cassandra Hamilton & Peter Q. Leung & Jens Meiler & Cristina E. Martina & Michael Whitney & Todd A. Ag, 2023. "Simultaneous selection of nanobodies for accessible epitopes on immune cells in the tumor microenvironment," Nature Communications, Nature, vol. 14(1), pages 1-20, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-022-35431-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.